QuidelOrtho Science BYTES Podcast

QuidelOrtho Science BYTES Podcast

By QuidelOrthoScienceEducationLife Sciences
Download on the App Store

QuidelOrtho Science BYTES Podcast episodes

  • Key facts about antibody titers in transfusion medicine that you can’t miss!

    Description: During this episode, Dr. Claudia Cohn will provide background on the role of antibody titers for diagnosis and monitoring performed in the transfusion medicine lab and its clinical applications.

    About our Speaker: 

    Dr. Claudia S. Cohn is the medical director of the blood bank laboratory and associate medical director of the HLA laboratory at the University of Minnesota.  She earned her Ph.D. in Immunology and Infectious Diseases from the Bloomberg School of Public Health at Johns Hopkins, working on the molecular biology and biochemistry of the protozoal; parasite Leishmania donovani. She went on to earn her medical degree from Louisiana State University School of Medicine in New Orleans, LA. After medical school, she finished a residency program in Pathology at New York-Presbyterian Hospital, Weill-Cornell College of Medicine, and a fellowship in Transfusion Medicine at the University of California, San Francisco.  In her current role at the University of Minnesota, she practices Clinical Pathology, oversees the blood bank, and teaches medical students.  Dr. Cohn’s research interests include platelet transfusions, alternative platelet storage solutions, HLA antibodies, and their role in solid organ transplants and platelet refractoriness. She focuses her efforts in two areas: patient blood management and platelet storage and utilization. Dr. Cohn was named in 2020 chief medical officer (CMO) for the AABB organization where she works to strategize and implement ways that achieve AABB’s mission through the development of policies and by engaging the communities it serves. 

    15 min
  • Your Lab Journey with the Rh System and Weak D

    Description: Discover the marvelous world of Rh D system’s complexity and why weak D is clinically relevant with Tony Casina.  


    About our Speaker: Tony S. Casina, MT(ASCP)SBB has worked in the blood banking industry for over 40 years with much of it in the commercial blood bank reagent manufacturers sector with hospital experience as a medical technologist and blood bank manager. Tony has provided technical support to laboratories throughout the world utilizing Ortho’s reagents and immunohematology test systems.  He has tested some of the most challenging antibody problems as part of his reference laboratory experience. Tony has been an active participant in the AABB serving on committees and currently on the AABB Board of Directors. He has contributed as a presenter to AABB and regional blood bank meetings educational programs. He was extensively involved in the development of the ORTHO VISION® Analyzer Platform

    12 min
  • The Impact of Innovation in the Health Care System with Dr. Palani Palaniappan

    Innovation can refer to something new or to a change made to an existing product, idea, or field. In this episode of Ortho Science Bytes let’s discuss what Innovation means, its importance in the current healthcare ecosystem, and how this concept can impact a Lab's performance.

     

    About our Speaker: 

    Chockalingam “Palani” Palaniappan, chief innovation officer at Ortho Clinical Diagnostics, is responsible for driving a culture of innovation, with a strong focus on enhancing product development productivity and processes. Prior to joining Ortho, Dr. Palani served as chief technology officer at Epic Sciences. Earlier, he was vice president for research and development in the cellular analysis division of Life Technologies Corp., a life sciences company in Eugene, Ore., providing labeling and detection services for DNA, RNA, protein and cells. He also served as head of molecular diagnostics research and development at Amersham Biosciences, a unit of GE Healthcare in Piscataway, N.J. Dr. Palani has served as a board member for Terumo Global Business Management and the State of Oregon Biosciences and Technology Initiatives, OTRADI & ONAMI. He also received the City of Lakewood Mayor’s Inspirational Leadership in Healthcare recognition in 2017. Dr. Palani holds a Ph.D. in biological sciences from Northern Illinois University and was a post-doctoral research fellow with the department of biochemistry and biophysics at the University of Rochester.

    19 min
  • The Role of High Throughput Antigen SARS-CoV-2 Testing in a Large, Metropolitan Hospital System

    Discuss with the Vice-Chair and Medical Director of Pathology for a large, metropolitan hospital the challenges the lab is facing with the surging number of COVID-19 cases and how a high throughput antigen test has contributed to meeting the demand for more testing. In this podcast episode, we will explore those key points and more.

    About our Speaker:

    Dr. Roush holds several positions within the Methodist Health System in the Dallas, Texas area, including Vice-Chair, Department of Pathology and Medical Director for Pathology, Transfusion Services, and the Transplant Immunology Laboratory. She also serves on several committees across the Methodist Health System. She is the author of several books and book chapters on the topic of blood banking and transfusion medicine in addition to articles that have been published in peer-reviewed journals.

    Reading Materials: https://www.mdpi.com/2077-0383/10/2/265 

    11 min
  • Safety Measures for Blood Products for SARS-CoV-2

    Description:

    There are several measures to ensure safety in blood products, and one of them is Pathogen Reduction Technology (PRT) which is used in some instances by blood banks to help make blood transfusions safer for patients by reducing the pathogen load of a broad range of disease-causing viruses, bacteria, and parasites and help reduce transfusion reactions in patients.   With COVID-19 rapidly spreading across the globe, blood banks may consider pathogen reduction technology as an added processing step to help ensure an adequate and safe supply of blood for patients.

    This Podcast will provide background on the virology of SARS-CoV-2 and PRT, as well as reviewing the scientific evidence supporting the usefulness of safety measures in protecting transfusion patients from this new virus.

     

    About our Speaker:

    Dr. Raymond P. Goodrich is the Executive Director of the Infectious Disease Research Center and a professor of Immunology and Pathology in the Department of Microbiology at Colorado State University.  His research group is currently focused on methods to safeguard blood transfusion products and to create and rapidly produce novel vaccine formulations that can be used to address infectious diseases. 

    25 min
  • Is Sars-Cov-2 transmitted by blood transfusion?

    Can Sars-Cov-2, the virus that causes COVID-19, be transmitted by blood transfusion? In this podcast episode, we will discuss with an Infectious Disease Specialist key points behind the precedent for respiratory viruses, factors to consider in an assessment for a pathogen to cause transfusion-transmitted infection, the data available, and the recommendations to maintain blood safety.

     

    About our Speaker: Written on the promotional piece: Dr. Louis Katz is currently the Chief Medical Officer of Mississippi Valley Regional Blood Center.   Dr. Katz is a board-certified internist and infectious diseases specialist who trained at the University of Iowa.  He is an Adjunct Clinical Professor of Internal Medicine at the Roy and Lucille Carver College of Medicine, former Chief Medical Officer at America’s Blood Centers in Washington, DC, an ABC past president, former board member, and a past chair of its Scientific, Medical and Technical committee.  His transfusion medicine career has been dominated by attention to transfusion-transmitted infections. He has served multiple terms as the chair of the AABB Transfusion Transmitted Diseases Committee and served on many AABB committees and working groups.  Dr. Katz is on the Editorial Board of the journal Transfusion, has served on the FDA Blood Products Advisory Committee as a member, industry representative, and chair, and is a current member of the HHS Advisory Committee on Blood and Tissue Safety and Availability. He has been the author of more than sixty peer reviewed publications and book chapters.  

    13 min
  • Do antibodies to COVID-19 disappear? A conversation with Dr. Akiko Iwasaki

    In this podcast episode, Dr. Akiko Iwasaki discusses the type of immune response developed in a person with COVID-19 as well as the role of the antibodies in the course of the pandemic and how the antibody tests can contribute to its management. 

     

    About our Speaker: Dr. Akiko Iwasaki received her Ph.D. from the University of Toronto (Canada) in 1998, and her postdoctoral training from the National Institutes of Health (USA) (1998-2000). She joined Yale University (USA) as a faculty in 2000, and currently is the Waldemar Von Zedtwitz Professor in the Department of Immunobiology and a Professor in the Department of Molecular, Cellular, and Developmental Biology at Yale University. She is also a principal investigator at the Howard Hughes Medical Institute. Her research interests among others include innate immunity, T cell immunity and her research focuses on the mechanisms of immune defense against viruses at the mucosal surfaces. Her laboratory is interested in how innate recognition of viral infections lead to the generation of adaptive immunity, and how adaptive immunity mediates protection against subsequent viral challenge. Most recently, Dr. Iwasaki has delved into research looking at the immune response of COVID-19 patients and sex differences in SARS-CoV-2 infection. 

     

    READING MATERIALS:

    • The New York Times. Your Coronavirus Antibodies Are Disappearing. Should You Care? July 27th/2020 https://nyti.ms/30U14v0 

    • The New York Times. Scared that COVID-19 Immunity won’t last? Don’t be. July 31st/2020 https://nyti.ms/2Pb6Dj1 

    12 min
  • What We Know About COVID-19 and Immunity

    Do antibodies really provide immunity against COVID-19? Are serological tests available today reliable enough to guide such critical decisions? In this episode, we will explore in detail the answers to those questions based on currently available scientific information.

     

    About our Speaker: 

    Dr. Fernando Chaves, MD, serves as the global head of medical, clinical, and scientific affairs for Ortho Clinical Diagnostics. In his role, Dr. Chaves is responsible for clinical trials, new product development, and key opinion leader relationships.

    Dr. Chaves is a board-certified anatomical and clinical pathologist, with further certification in hematopathology, combining 5+ years of executive-level leadership with 10+ years of simultaneous diagnostic industry achievements and clinical hematopathology experience. He is a pioneering researcher and executive credited with discovering, testing, and bringing to market new laboratory tests for multiple medical conditions, predominantly sepsis-related and hematologic diseases. Dr. Chaves is recognized as an expert leader in the diagnostic industry with a passion for helping medical companies develop products that are immediately beneficial to patients in the most economical, efficient manner

    21 min
  • The Association Between Blood Type and COVID-19

    In this episode of Ortho Science BYTES, speaker Tony Casina reviews the history of the association between blood type and development of diseases and whether literature answers the question if there are certain blood types associated with COVID-19.

     

    About our Speaker: 

    Tony S. Casina, MT(ASCP)SBB has worked in the blood banking industry for over 40 years with much of it in the commercial blood bank reagent manufacturers sector with hospital experience as a medical technologist and blood bank manager. Tony has provided technical support to laboratories throughout the world utilizing Ortho’s reagents and immunohematology test systems.  He has tested some of the most challenging antibody problems as part of his reference laboratory experience. Tony has been an active participant in the AABB serving on committees and currently on the AABB Board of Directors. He has contributed as a presenter to AABB and regional blood bank meetings educational programs. He was extensively involved in the development of the ORTHO VISION® Analyzer Platform.

     

    References and Links: 

    • https://www.redcrossblood.org/donate-blood/blood-types.html 
  • Beyond immunohaematology: The role of the ABO blood group in human diseases, Giancarlo Maria Liumbruno & Massimo Franchini, Blood Transfus 2013; 11: 491-9, doi 10.2450/2013.0152-13. 
  • Annals of Hematology. Blood type and outcomes in patients with COVID-19. Christopher A. Latz, Charles DeCarlo, Laura Boitano, C. Y. Maximilian Png, Rushad Patell, & Mark F. July 2020 
  • The New England Journal of Medicine. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. The Severe Covid-19 GWAS Group* Dr. Ellinghaus, Ms. Degenhardt, Drs. Valenti, Franke, Karlsen. June 17, 2020
  • Garratty G. Blood groups and disease: a historical perspective. Transfus Med Rev 2000; 14: 291-301.
    • 15 min
  • Why Convalescent Plasma for COVID-19

    Why Convalescent Plasma for COVID-19?

     

    In this episode of Ortho Science BYTES host, Matt Dawson discuss why COVID-19 Convalescent Plasma has been used as a treatment and what are the scientific and clinical basis for its use with Dr. Lily Li.  

     

    About our Speaker: 

    Dr. Lily Li is the Medical Safety Officer at Ortho Clinical Diagnostics responsible for evaluating potential medical risks and guiding risk mitigation of all marketed products. She also serves as a Medical Director at Medical and Scientific Affairs providing evidence-based support to Ortho’s current and future products. Prior to joining Ortho, Lily had ten years of pharmaceutical R&D experience in Johnson & Johnson and led and advanced multiple programs of biologics and cell therapies through development. Lily obtained her Medical Degree from Peking University, China, and her Ph.D. in Immunology from the University of Alberta, Canada. She completed her post-doctoral training at the Scripps Research Institutes, San Diego. Lily is the author of more than 40 scientific articles and has filed 17 patent applications.

     

    References and Links: 

    • Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma; Shen at al. JAMA. 2020;323(16):1582-1589. Published online March 27, 2020.
  • The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study, Duan et al, Mar 2020, medRxiv preprint doi: https://doi.org/10.1101/2020.03.16.20036145
  • Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial, Li et al, JAMA, 2020 Jun 3. doi: 10.1001/jama.2020.10044.
  • Convalescent plasma treatment of severe COVID-19: A matched 1 control study, S. T. H. Liu, et al, May 22, 2020, medRxiv preprint doi: https://doi.org/10.1101/2020.05.20.20102236.
  • Convalescent Plasma to Treat COVID-19. Possibilities and Challenges; John D. Roback, MD, PhD; Jeannette Guarner, MD. JAMA April 28, 2020 Volume 323, Number 16
  • The convalescent sera option for containing COVID-19 Arturo Casadevall, Liise-anne Pirofski. J Clin Invest. 2020;130(4):1545-1548.
    •  FDA site https://www.fda.gov/
    18 min

About QuidelOrtho Science BYTES Podcast

From the publisher's feed

Today’s healthcare marketplace is more complex than ever. Labs today are faced with increasing regulatory and quality demands coupled with a shortage of skilled labor. QuidelOrtho is…